Biologic Concentration Testing in Inflammatory Bowel Disease

por Vaughn, Byron P., Sandborn, William J., Cheifetz, Adam S.
Publicado 2015

Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies

por Bosworth, Brian P., Sandborn, William J., Rubin, David T., Harper, Joseph R.
Publicado 2016

Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease

por Arulanandan, Ahilan, Dulai, Parambir S, Singh, Siddharth, Sandborn, William J, Kalmaz, Denise
Publicado 2016

Prevalence of Fistulizing Crohn’s Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis

por Schwartz, David A, Tagarro, Ignacio, Carmen Díez, Mary, Sandborn, William J
Publicado 2019

Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group st...

por Vande Casteele, Niels, Jakate, Abhijeet, McNamee, Brian, Sandborn, William J.
Publicado 2020

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

por Dulai, Parambir S., Osterman, Mark T., Lasch, Karen, Cao, Charlie, Riaz, Faisal, Sandborn, William J.
Publicado 2019

Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases

por Singh, Siddharth, Heien, Herbert C., Sangaralingham, Lindsey, Shah, Nilay D., Sandborn, William J.
Publicado 2021

Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program

por Sandborn, William J., Vermeire, Severine, Tyrrell, Helen, Hassanali, Azra, Lacey, Stuart, Tole, Swati, Tatro, Amanda R.
Publicado 2020

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

por Sandborn, William J, Targan, Stephan R, Byers, Vera S, Rutty, Dean A, Mu, Hua, Zhang, Xun, Tang, Tom
Publicado 2013

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

por Wade, Janet R., Parker, Gerry, Kosutic, Gordana, Feagen, Brian G., Sandborn, William J., Laveille, Christian, Oliver, Ruth
Publicado 2015

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

por Sandborn, William J, Colombel, Jean-Frédéric, Panaccione, Remo, Dulai, Parambir S, Rosario, Maria, Cao, Charlie, Barocas, Morris, Lasch, Karen
Publicado 2019

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis

por Vong, Camille, Martin, Steven W., Deng, Chenhui, Xie, Rujia, Ito, Kaori, Su, Chinyu, Sandborn, William J., Mukherjee, Arnab
Publicado 2021

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues

por Peyrin-Biroulet, Laurent, Sandborn, William J., Panaccione, Remo, Domènech, Eugeni, Pouillon, Lieven, Siegmund, Britta, Danese, Silvio, Ghosh, Subrata
Publicado 2021

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials

por Hanauer, Stephen, Sandborn, William J, Colombel, Jean-Frederic, Vermeire, Severine, Petersson, Joel, Kligys, Kristina, Zhou, Qian, Lazar, Andreas, Reinisch, Walter
Publicado 2019

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies

por Mukherjee, Arnab, Tsuchiwata, Shinichi, Nicholas, Timothy, Cook, Jack A., Modesto, Irene, Su, Chinyu, D’Haens, Geert R., Sandborn, William J.
Publicado 2022

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program

por Sandborn, William J., Sands, Bruce E., Vermeire, Séverine, Leung, Yvette, Guo, Xiang, Modesto, Irene, Su, Chinyu, Wang, Wenjin, Panés, Julian
Publicado 2022

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

por Loftus, Edward V, Vermeire, Séverine, Feagan, Brian G, Le Brun, Franck-Olivier, Oortwijn, Alessandra, Moerch, Ulrik, Sandborn, William J, Hibi, Toshifumi
Publicado 2022

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

por Peyrin-Biroulet, Laurent, Cieza, Alarcos, Sandborn, William J, Coenen, Michaela, Chowers, Yehuda, Hibi, Toshifumi, Kostanjsek, Nenad, Stucki, Gerold, Colombel, Jean-Frédéric
Publicado 2011

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE...

por Panaccione, Remo, Sandborn, William J, D’Haens, Geert, Wolf, Douglas C, Berg, Sofie, Maa, Jen-fue, Petersson, Joel, Robinson, Anne M
Publicado 2018

Sa503 MACHINE LEARNING OUTPERFORMS TRADITIONAL RISK MODEL IN IDENTIFYING HIGH-NEED, HIGH-COST PATIENTS WITH INFLAMMATORY BOWEL DISEASES IN A NATIONALLY REPRESENTATIVE COHORT

por Nguyen, Nghia H., Patel, Sagar, Gabunilas, Jason, Qian, Alexander, Cecil, Alan, Ohno-Machado, Lucila, Sandborn, William J., Singh, Siddharth, Chen, Peter
Publicado 2021